Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Apr 24, 2024
Product Development

Clinical report: Sanofi data advances pair of autoimmune disease mechanisms

Plus: Neurocrine hits in Phase II depression study and updates from Cerevel, Sage, Ventus, Lilly and AbbVie
BioCentury | Aug 18, 2018
Regulation

Pediatric push

Why companies should invest in data, alliances to support pediatric extrapolation
BioCentury | May 5, 2018
Product Development

Rebuilding Biogen’s brain

What Biogen is building in neurology
BioCentury | Apr 24, 2018
Company News

Biogen looks to ex-U.S. markets for growth

BioCentury | Dec 15, 2016
Translation in Brief

Fore score

How Cerecor's forebrain-specific GRIA antagonist sidelines GRIA's side effects
BioCentury | Nov 2, 2016
Clinical News

Fycompa: Ph III started

Items per page:
1 - 10 of 68